| Literature DB >> 33062173 |
James R Annand1,2, Andrew R Henderson2, Kyle S Cole3, Aaron J Maurais3, Jorge Becerra2, Yejun Liu2, Eranthie Weerapana3, Angela N Koehler4, Anna K Mapp1,2, Corinna S Schindler1,2.
Abstract
The small molecule gibberellin JRA-003 was identified as an inhibitor of the NF-kB (nuclear kappa-light-chain-enhancer of activated B cells) pathway. Here we find that JRA-003 binds to and significantly inhibits the nuclear translocation of pathway-activating kinases IKKα (IκB kinase alpha) and IKKβ (IκB kinase beta). Analogs of JRA-003 were synthesized and NF-κB-inhibiting gibberellins were found to be cytotoxic in cancer-derived cell lines (HS 578T, HCC 1599, RC-K8, Sud-HL4, CA 46, and NCIH 4466). Not only was JRA-003 identified as the most potent synthetic gibberellin against cancer-derived cell lines, it displayed no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC). This selectivity suggests a promising approach for the development of new therapeutics.Entities:
Year: 2020 PMID: 33062173 PMCID: PMC7549252 DOI: 10.1021/acsmedchemlett.9b00613
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345